Developer docs
API playgroundTry for free, no card

Search company profiles

Innatoss Laboratories BV

Full company profile

uuid002mk6t

Namestring
Innatoss Laboratories BV
Legal namestring
Innatoss Laboratories BV
Websiteurl
innatoss.com
Company typeenum
Private
Founded yearint
2012
Short descriptiontext

Innatoss Laboratories is a Dutch ISO/IEC 17025-accredited diagnostic laboratory specializing in multi-test Lyme disease screening, serving Dutch municipalities, water boards, nature organizations, and consumers via its Jaarlijkse Lyme Screening program and LymePaspoort consumer product.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersOss, Netherlands
HQ citystring
Oss
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
Lyme disease diagnostics, Serological testing services, Occupational health screening, ELISA laboratory testing, Tick-borne disease monitoring
Industry2 codes
PRIMARYHLAFAMAK
Occupational Health & Employer Testing Laboratories
SECONDARYHLAFAMAB
Clinical Chemistry & Immunoassay Laboratories
NAICS code3 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Diagnostic laboratory services
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1LymePaspoort (B2C/B2B small)
TypeOne Time License
Description

One-time purchase of the LymePaspoort test kit through the Innatoss web shop, including blood draw kit, lab testing with at least 3 ELISAs, secure email results, and phone consultation. Currently temporarily unavailable (expected back September).

innatoss.com
2Jaarlijkse Lyme Screening (Annual Organizational Screening)
TypeSubscription Recurring
Description

Annual recurring screening service for organizations with 10+ employees working outdoors. Includes education, on-site blood draws, lab testing, personal results with follow-up, management reporting, and evaluation. Pricing is custom quote-based depending on participant count and number of site visits.

innatoss.com
3Additional disease testing
TypeProfessional Services
Description

Add-on testing for related conditions such as Tick-borne encephalitis (TBE), Weil's disease, and vaccinations, offered as supplements to the annual screening program for organizations.

innatoss.com
4COVID-19 and Q-fever research projects
TypeProfessional Services
Description

Commissioned research projects (e.g., BREAK COVID for LUMC, Q-fever vaccine studies for international partners) generating revenue through grants and research commissions. Innatoss provides study design support, participant recruitment, blood logistics, and laboratory testing.

innatoss.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details2 tiers
1LymePaspoort for consumers and small organizations — one-time purchase, temporarily unavailable
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Price not publicly disclosed. Currently temporarily unavailable (expected back 1 September). Blood draw costs are included. Payment via iDEAL or bank transfer.

innatoss.com
2Jaarlijkse Lyme Screening for organizations (10+ employees)
ModelSubscriptionBilling cadenceAnnual
Notes

Pricing is custom/quote-based, depending on number of participants and number of site visits. Minimum 10 participants required. Includes management reporting for organizations.

innatoss.com
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 2 records shown
1LymePaspoort
Description

Annual Borrelia testing product for individuals and small organizations to detect Lyme infection early.

innatoss.com
+1 more record
Core offering1 text field

Innatoss Laboratories is a Dutch independent diagnostic laboratory that runs serological and cellular immunological tests for infectious diseases, principally Lyme disease. Its two commercial products are the LymePaspoort—an annual Borrelia antibody test kit ordered online and processed in its Oss lab using at least three simultaneous CE-marked ELISAs with confirmatory immunoblot—and the Jaarlijkse Lyme Screening (JLS), an annual on-site screening program for organizations with employees working outdoors, including education, phlebotomy, multi-test ELISA analysis, scientist-reviewed results, secure email delivery, and aggregate management reporting for Risk Inventory & Evaluation (RI&E) compliance under Dutch ARBO law.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 20,000 Lyme tests conducted per year across organizational and consumer programs
+3 more records
Product overview1 text field

Innatoss Laboratories is a research-intensive diagnostic laboratory specializing in Lyme disease testing services. The company operates two core testing products: the LymePaspoort for individual consumers, freelancers, and small organizations (ordered online with home blood sampling kit and results via secure email), and the Jaarlijkse Lyme Screening (Annual Lyme Screening) for organizations with 10+ employees working outdoors. Both services use a multi-test approach with at least three simultaneous ELISA tests (Euroimmun Borrelia IgG, Euroimmun Borrelia IgM, and Zeus VlsE1-OspC), with confirmatory immunoblot testing available as an add-on. The company holds ISO/IEC 17025:2017 accreditation and NEN 7510:2024 compliance, working exclusively with CE-marked tests. In addition to testing services, Innatoss conducts extensive research on infectious diseases including Lyme, Q-fever, and COVID-19, with past projects including cPass testing, QuantiFERON SARS-CoV-2 validation, ID-Lyme device development, and the ongoing ESPRIT platform development with University of Twente.

Product and service3 records
1LymePaspoort
CategoryConsumer/SMB diagnostic testing product
Description

Annual Borrelia antibody testing service for consumers, freelancers, and small organizations. Customers order online, receive a blood sampling kit, provide a blood sample at a local phlebotomy station, and receive results via secure email with follow-up consultation for abnormal results, including an annual personal baseline (null measurement) for detecting new infections.

2Jaarlijkse Lyme Screening (Annual Lyme Screening)
CategoryB2B occupational health screening service
Description

Annual organizational Lyme screening program for employers with 10+ outdoor workers, providing education, on-site blood draws by Innatoss nursing staff, in-lab analysis with at least three CE-marked ELISA tests, scientist-reviewed personal results delivered by secure email, and management reporting for Risk Inventory & Evaluation (RI&E) under Dutch ARBO law, with optional add-ons for TBE, Weil's disease, and vaccinations.

3Teken-toolbox (Tick Toolbox)
CategoryEducational/awareness service add-on
Description

Educational presentation service (approximately 45 minutes to 1 hour) for employers covering tick prevention, bite prevention, proper tick removal, and Lyme disease symptom recognition, deliverable on-site by Innatoss staff or self-administered by the employer, used to support the Jaarlijkse Lyme Screening program.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
1Universiteit van Twente (University of Twente)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on the ESPRIT project to develop a novel Lyme diagnostic platform that not only measures antibodies but also directly detects the presence of Borrelia bacteria. The platform combines technologies from multiple partners. Innatoss contributes expertise, knowledge, and research material including serum samples from the JLS program spanning from shortly after infection to years later.

innatoss.com
2Vysens (Hengelo)
Strategic tierCoreTypeTechnology or Integration
Description

Partner in the ESPRIT project focusing on antibody analysis, including studying how strongly antibodies bind. This provides additional information about how the immune system responds, which is used to develop a more sensitive Lyme diagnostic.

innatoss.com
Strategic tierCoreTypeTechnology or Integration
Description

Partner in the ESPRIT project working on techniques to measure bacteria directly. This is a significant challenge specifically for Lyme disease, where bacterial loads are typically very low.

4Stichting IMtest
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Early COVID-19 collaboration with a group of 10 medical students operating a MoLab (mobile lab) across the Netherlands. Innatoss validated available tests and processed and evaluated results professionally. This partnership enabled rapid scaling of COVID-19 antibody testing across the country.

innatoss.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing collaboration on Q-fever vaccine development. Q-Vaxcelerate project combined Innatoss's experience with cellular tests and Q-fever with the presence of many Q-fever patients in the region. Worked with MGH, Epivax, Yale, Colorado State University, and Oxford University on a next-generation Q-fever vaccine with fewer side effects. Followed by Q-fever vaccine study in Brisbane.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner in the ID-Lyme project (EU Fast Track to Innovation, 2016) for the design and manufacture of a point-of-care cellular immunity testing device for use at GP offices.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic partner in the ID-Lyme EU Fast Track to Innovation project for cellular immunity testing device development.

8DIARECT (Freiburg, Germany)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner in the ID-Lyme EU Fast Track to Innovation project, contributing antigen expertise for the cellular immunity testing device.

innatoss.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

International partner in the Q-fever vaccine study in Brisbane, investigating immune response and side effects after vaccination with Q-VAX. Follow-up project to Q-Vaxcelerate, also involving Australian Rickettsial Reference Lab and Sullivan Nicolaides Pathology.

10Australian Rickettsial Reference Lab / Sullivan Nicolaides Pathology (Australia)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Australian pathology partners in the Q-fever vaccine study in Brisbane, collaborating with Massachusetts General Hospital and University of Queensland.

innatoss.com
11Stichting Tekenbeetziekten (Dutch Tick-Borne Diseases Foundation)
Strategic tierCoreTypeGTM or Marketing Partner
Description

Active collaboration on awareness campaigns including the annual Week van de Teek (Week of the Tick). Innatoss sponsors the campaign and is present daily at the American schoolbus tour. Shared goal of making the Netherlands more aware of tick and tick-borne disease risks. Foundation manages a tick information route and provides educational materials.

innatoss.com
Strategic tierCoreTypeGTM or Marketing Partner
Description

Patient association partnership for awareness and advocacy. Collaboration on the Week van de Teek campaign and shared mission to improve Lyme disease awareness and patient outcomes in the Netherlands.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

EU-funded partnership to develop a novel Lyme borreliosis clinical decision system. Innatoss and MediSapiens received EU grant to personalize Lyme diagnostics using computational methods.

14Treeport (West-Brabant tree nursery cooperative)
Strategic tierMinorTypeGTM or Marketing Partner
Description

Cooperative association of ~180 tree nurseries in West-Brabant. Innatoss presented at Treeport Café to introduce Lyme screening to the tree nursery sector, which previously had no formal tick exposure assessment. Potential future collaboration on screening and research.

innatoss.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global manufacturer of ELISA platforms, immunoassay reagents, and quality controls used in clinical laboratories. Comparable as a supplier of testing infrastructure and a potential competitor if Bio-Rad expands Lyme diagnostic kits or automated serology platforms.

TypeDirect peer
Description

Dutch specialty diagnostics laboratory operating a national network focused on blood-based testing and screening services. Comparable as a direct Dutch competitor for occupational screening contracts and a blood draw station partner listed in Innatoss's network.

TypeOthers
Description

Manufacturer of CE-marked ELISA test kits including the Borrelia IgG and IgM assays that Innatoss uses as part of its ≥3-ELISA panel. Comparable as a key upstream technology partner and potential competitor if Euroimmun bundles similar multi-test panels for other clinical labs.

TypeEmerging player
Description

Specialty diagnostics company focused on tick-borne and infectious disease cellular immunity testing (T-SPOT technology). Comparable as an emerging competitor in the cellular immunity testing space, particularly relevant given Innatoss's patented WOLF point-of-care device and Q-Vaxcelerate work.

5SALTRO
TypeDirect peer
Description

Dutch regional clinical diagnostics provider offering laboratory testing, occupational health screening, and preventive services to employers and healthcare providers. Comparable as a direct competitor in the Dutch organizational screening and occupational health market.

TypeBroad incumbent
Description

Global molecular diagnostics and sample-preparation technology provider whose QuantiFERON SARS-CoV-2 cellular immunity test was validated by Innatoss in 2021. Comparable as a potential partner or competitor in cellular immunity assays and Lyme/COVID diagnostics.

TypeBroad incumbent
Description

International clinical laboratory group with strong presence in specialty and esoteric diagnostics across Europe. Comparable as a potential competitor or commercialization partner for Innatoss's Lyme serology platform and ESPRIT direct-detection assay.

TypeBroad incumbent
Description

Europe's largest medical diagnostics services provider operating across clinical chemistry, immunology, and specialty testing. Comparable as a potential competitor in occupational health screening programs and a partner candidate for expanding Innatoss's Lyme services into additional European markets.

TypeBroad incumbent
Description

One of Europe's largest clinical laboratory networks offering a broad menu of diagnostic tests across multiple specialties. Innatoss already partners with Unilabs Medlon/SHO for blood draw station services; Unilabs represents the kind of scaled incumbent that could compete on Lyme serology with greater geographic reach and lower unit costs.

TypeBroad incumbent
Description

Former partner on the Sofia-2 Lyme Plus point-of-care test that Innatoss helped adapt for European Borrelia variants. Comparable as a diagnostic platform incumbent whose withdrawal from European Lyme demonstrates the competitive dynamics of platform-based Lyme testing.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Innatoss Laboratories BV

Diagnostic laboratory servicesinnatoss.com

Innatoss Laboratories is a Dutch ISO/IEC 17025-accredited diagnostic laboratory specializing in multi-test Lyme disease screening, serving Dutch municipalities, water boards, nature organizations, and consumers via its Jaarlijkse Lyme Screening program and LymePaspoort consumer product.

Innatoss Laboratories BV firmographics

Firmographics
Name
Innatoss Laboratories BV
Legal name
Innatoss Laboratories BV
Website
https://innatoss.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
1–10 employees
Short description
Innatoss Laboratories is a Dutch ISO/IEC 17025-accredited diagnostic laboratory specializing in multi-test Lyme disease screening, serving Dutch municipalities, water boards, nature organizations, and consumers via its Jaarlijkse Lyme Screening program and LymePaspoort consumer product.
Ownership category
akta.pro rank

Innatoss Laboratories BV industry classification

Industry
Product category
Diagnostic laboratory services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAFAMAK
Occupational Health & Employer Testing Laboratories
SECONDARYHLAFAMAB
Clinical Chemistry & Immunoassay Laboratories

Keywords

  • Lyme disease diagnostics
  • Serological testing services
  • Occupational health screening
  • ELISA laboratory testing
  • Tick-borne disease monitoring

Where Innatoss Laboratories BV is headquartered

Location

Headquarters

HQ city
Oss
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

Innatoss Laboratories BV business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. LymePaspoort (B2C/B2B small): One-time purchase of the LymePaspoort test kit through the Innatoss web shop, including blood draw kit, lab testing with at least 3 ELISAs, secure email results, and phone consultation. Currently temporarily unavailable (expected back September).
  2. Jaarlijkse Lyme Screening (Annual Organizational Screening): Annual recurring screening service for organizations with 10+ employees working outdoors. Includes education, on-site blood draws, lab testing, personal results with follow-up, management reporting, and evaluation. Pricing is custom quote-based depending on participant count and number of site visits.
  3. Additional disease testing: Add-on testing for related conditions such as Tick-borne encephalitis (TBE), Weil's disease, and vaccinations, offered as supplements to the annual screening program for organizations.
  4. COVID-19 and Q-fever research projects: Commissioned research projects (e.g., BREAK COVID for LUMC, Q-fever vaccine studies for international partners) generating revenue through grants and research commissions. Innatoss provides study design support, participant recruitment, blood logistics, and laboratory testing.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goLymePaspoort for consumers and small organizations — one-time purchase, temporarily unavailable
SubscriptionAnnualJaarlijkse Lyme Screening for organizations (10+ employees)

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Innatoss Laboratories BV product offering

Product offering

Core offering

Innatoss Laboratories is a Dutch independent diagnostic laboratory that runs serological and cellular immunological tests for infectious diseases, principally Lyme disease. Its two commercial products are the LymePaspoort—an annual Borrelia antibody test kit ordered online and processed in its Oss lab using at least three simultaneous CE-marked ELISAs with confirmatory immunoblot—and the Jaarlijkse Lyme Screening (JLS), an annual on-site screening program for organizations with employees working outdoors, including education, phlebotomy, multi-test ELISA analysis, scientist-reviewed results, secure email delivery, and aggregate management reporting for Risk Inventory & Evaluation (RI&E) compliance under Dutch ARBO law.

Product overview

Innatoss Laboratories is a research-intensive diagnostic laboratory specializing in Lyme disease testing services. The company operates two core testing products: the LymePaspoort for individual consumers, freelancers, and small organizations (ordered online with home blood sampling kit and results via secure email), and the Jaarlijkse Lyme Screening (Annual Lyme Screening) for organizations with 10+ employees working outdoors. Both services use a multi-test approach with at least three simultaneous ELISA tests (Euroimmun Borrelia IgG, Euroimmun Borrelia IgM, and Zeus VlsE1-OspC), with confirmatory immunoblot testing available as an add-on. The company holds ISO/IEC 17025:2017 accreditation and NEN 7510:2024 compliance, working exclusively with CE-marked tests. In addition to testing services, Innatoss conducts extensive research on infectious diseases including Lyme, Q-fever, and COVID-19, with past projects including cPass testing, QuantiFERON SARS-CoV-2 validation, ID-Lyme device development, and the ongoing ESPRIT platform development with University of Twente.

Differentiator

Problem solved

Functional benefit

Brands

  • LymePaspoort: Annual Borrelia testing product for individuals and small organizations to detect Lyme infection early.
  • Jaarlijkse Lyme Screening

Products and services

  • LymePaspoort Annual Borrelia antibody testing service for consumers, freelancers, and small organizations. Customers order online, receive a blood sampling kit, provide a blood sample at a local phlebotomy station, and receive results via secure email with follow-up consultation for abnormal results, including an annual personal baseline (null measurement) for detecting new infections.
  • Jaarlijkse Lyme Screening (Annual Lyme Screening) Annual organizational Lyme screening program for employers with 10+ outdoor workers, providing education, on-site blood draws by Innatoss nursing staff, in-lab analysis with at least three CE-marked ELISA tests, scientist-reviewed personal results delivered by secure email, and management reporting for Risk Inventory & Evaluation (RI&E) under Dutch ARBO law, with optional add-ons for TBE, Weil's disease, and vaccinations.
  • Teken-toolbox (Tick Toolbox) Educational presentation service (approximately 45 minutes to 1 hour) for employers covering tick prevention, bite prevention, proper tick removal, and Lyme disease symptom recognition, deliverable on-site by Innatoss staff or self-administered by the employer, used to support the Jaarlijkse Lyme Screening program.

Quantifiable outcome

  • Over 20,000 Lyme tests conducted per year across organizational and consumer programs
  • +3 more outcomes

Companies that use Innatoss Laboratories BV

Customer profile

Named customers11 records

Segments3 records

Ideal customer profiles2 records

Innatoss Laboratories BV technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

Feature6 records

Innatoss Laboratories BV partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered core and minor.

  • Universiteit van Twente (University of Twente)coreStrategic or Co-development PartnerCollaboration on the ESPRIT project to develop a novel Lyme diagnostic platform that not only measures antibodies but also directly detects the presence of Borrelia bacteria. The platform combines technologies from multiple partners. Innatoss contributes expertise, knowledge, and research material including serum samples from the JLS program spanning from shortly after infection to years later.
  • Vysens (Hengelo)coreTechnology or IntegrationPartner in the ESPRIT project focusing on antibody analysis, including studying how strongly antibodies bind. This provides additional information about how the immune system responds, which is used to develop a more sensitive Lyme diagnostic.
  • OccamDx (formerly ECsens, Enschede)coreTechnology or IntegrationPartner in the ESPRIT project working on techniques to measure bacteria directly. This is a significant challenge specifically for Lyme disease, where bacterial loads are typically very low.
  • Stichting IMtestcoreStrategic or Co-development PartnerEarly COVID-19 collaboration with a group of 10 medical students operating a MoLab (mobile lab) across the Netherlands. Innatoss validated available tests and processed and evaluated results professionally. This partnership enabled rapid scaling of COVID-19 antibody testing across the country.
  • Massachusetts General Hospital — Vaccin and Immunotherapy Center (Boston, USA)coreStrategic or Co-development PartnerLong-standing collaboration on Q-fever vaccine development. Q-Vaxcelerate project combined Innatoss's experience with cellular tests and Q-fever with the presence of many Q-fever patients in the region. Worked with MGH, Epivax, Yale, Colorado State University, and Oxford University on a next-generation Q-fever vaccine with fewer side effects. Followed by Q-fever vaccine study in Brisbane.
  • NPK design (Leiden, Netherlands)minorStrategic or Co-development PartnerPartner in the ID-Lyme project (EU Fast Track to Innovation, 2016) for the design and manufacture of a point-of-care cellular immunity testing device for use at GP offices.
  • University of Vienna (Universität Wien, Austria)minorStrategic or Co-development PartnerAcademic partner in the ID-Lyme EU Fast Track to Innovation project for cellular immunity testing device development.
  • DIARECT (Freiburg, Germany)minorStrategic or Co-development PartnerPartner in the ID-Lyme EU Fast Track to Innovation project, contributing antigen expertise for the cellular immunity testing device.
  • University of Queensland (Australia)coreStrategic or Co-development PartnerInternational partner in the Q-fever vaccine study in Brisbane, investigating immune response and side effects after vaccination with Q-VAX. Follow-up project to Q-Vaxcelerate, also involving Australian Rickettsial Reference Lab and Sullivan Nicolaides Pathology.
  • Australian Rickettsial Reference Lab / Sullivan Nicolaides Pathology (Australia)coreStrategic or Co-development PartnerAustralian pathology partners in the Q-fever vaccine study in Brisbane, collaborating with Massachusetts General Hospital and University of Queensland.
  • Stichting Tekenbeetziekten (Dutch Tick-Borne Diseases Foundation)coreGTM or Marketing PartnerActive collaboration on awareness campaigns including the annual Week van de Teek (Week of the Tick). Innatoss sponsors the campaign and is present daily at the American schoolbus tour. Shared goal of making the Netherlands more aware of tick and tick-borne disease risks. Foundation manages a tick information route and provides educational materials.
  • Lymevereniging (Dutch Lyme Association)coreGTM or Marketing PartnerPatient association partnership for awareness and advocacy. Collaboration on the Week van de Teek campaign and shared mission to improve Lyme disease awareness and patient outcomes in the Netherlands.
  • MediSapiens (Finland)minorStrategic or Co-development PartnerEU-funded partnership to develop a novel Lyme borreliosis clinical decision system. Innatoss and MediSapiens received EU grant to personalize Lyme diagnostics using computational methods.
  • Treeport (West-Brabant tree nursery cooperative)minorGTM or Marketing PartnerCooperative association of ~180 tree nurseries in West-Brabant. Innatoss presented at Treeport Café to introduce Lyme screening to the tree nursery sector, which previously had no formal tick exposure assessment. Potential future collaboration on screening and research.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Innatoss Laboratories BV competitors and assessment

Company assessment

Broad incumbents

  • Bio-Rad Laboratories: Global manufacturer of ELISA platforms, immunoassay reagents, and quality controls used in clinical laboratories. Comparable as a supplier of testing infrastructure and a potential competitor if Bio-Rad expands Lyme diagnostic kits or automated serology platforms.
  • Qiagen: Global molecular diagnostics and sample-preparation technology provider whose QuantiFERON SARS-CoV-2 cellular immunity test was validated by Innatoss in 2021. Comparable as a potential partner or competitor in cellular immunity assays and Lyme/COVID diagnostics.
  • Cerba Healthcare: International clinical laboratory group with strong presence in specialty and esoteric diagnostics across Europe. Comparable as a potential competitor or commercialization partner for Innatoss's Lyme serology platform and ESPRIT direct-detection assay.
  • Synlab: Europe's largest medical diagnostics services provider operating across clinical chemistry, immunology, and specialty testing. Comparable as a potential competitor in occupational health screening programs and a partner candidate for expanding Innatoss's Lyme services into additional European markets.
  • Unilabs: One of Europe's largest clinical laboratory networks offering a broad menu of diagnostic tests across multiple specialties. Innatoss already partners with Unilabs Medlon/SHO for blood draw station services; Unilabs represents the kind of scaled incumbent that could compete on Lyme serology with greater geographic reach and lower unit costs.
  • QuidelOrtho: Former partner on the Sofia-2 Lyme Plus point-of-care test that Innatoss helped adapt for European Borrelia variants. Comparable as a diagnostic platform incumbent whose withdrawal from European Lyme demonstrates the competitive dynamics of platform-based Lyme testing.

Direct peers

  • Star-SHL: Dutch specialty diagnostics laboratory operating a national network focused on blood-based testing and screening services. Comparable as a direct Dutch competitor for occupational screening contracts and a blood draw station partner listed in Innatoss's network.
  • SALTRO: Dutch regional clinical diagnostics provider offering laboratory testing, occupational health screening, and preventive services to employers and healthcare providers. Comparable as a direct competitor in the Dutch organizational screening and occupational health market.

Others

  • Euroimmun: Manufacturer of CE-marked ELISA test kits including the Borrelia IgG and IgM assays that Innatoss uses as part of its ≥3-ELISA panel. Comparable as a key upstream technology partner and potential competitor if Euroimmun bundles similar multi-test panels for other clinical labs.

Emerging players

  • Oxford Immunotec: Specialty diagnostics company focused on tick-borne and infectious disease cellular immunity testing (T-SPOT technology). Comparable as an emerging competitor in the cellular immunity testing space, particularly relevant given Innatoss's patented WOLF point-of-care device and Q-Vaxcelerate work.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Innatoss Laboratories BV financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Innatoss Laboratories BV leadership team

Management profile

Number of profiles

Profiles11 records

Innatoss Laboratories BV funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Innatoss Laboratories BV M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Innatoss Laboratories BV

What does Innatoss Laboratories BV do?

Innatoss Laboratories is a Dutch independent diagnostic laboratory that runs serological and cellular immunological tests for infectious diseases, principally Lyme disease. Its two commercial products are the LymePaspoort—an annual Borrelia antibody test kit ordered online and processed in its Oss lab using at least three simultaneous CE-marked ELISAs with confirmatory immunoblot—and the Jaarlijkse Lyme Screening (JLS), an annual on-site screening program for organizations with employees working outdoors, including education, phlebotomy, multi-test ELISA analysis, scientist-reviewed results, secure email delivery, and aggregate management reporting for Risk Inventory & Evaluation (RI&E) compliance under Dutch ARBO law.

Is Innatoss Laboratories BV a public or private company?

Innatoss Laboratories BV is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Innatoss Laboratories BV founded?

Innatoss Laboratories BV was founded in 2012. It employs 1 to 10 people.

Where is Innatoss Laboratories BV based?

Innatoss Laboratories BV is headquartered in Oss, Netherlands, in the Europe region.

How does Innatoss Laboratories BV make money?

Four revenue lines are on record. LymePaspoort (B2C/B2B small) is the primary driver. The others are jaarlijkse Lyme Screening (Annual Organizational Screening), additional disease testing and COVID-19 and Q-fever research projects.

Who are Innatoss Laboratories BV's main competitors?

Broad incumbents on record are Bio-Rad Laboratories, Qiagen, Cerba Healthcare, Synlab, Unilabs and QuidelOrtho. Direct peers are Star-SHL and SALTRO. Euroimmun is listed as an others. Oxford Immunotec is listed as an emerging player.

Does Innatoss Laboratories BV have an API?

No public API is recorded for Innatoss Laboratories BV.

What industry is Innatoss Laboratories BV in?

Innatoss Laboratories BV's product category is Diagnostic laboratory services. Its primary akta.pro industry code is HLAFAMAK, Occupational Health & Employer Testing Laboratories, with a secondary code of HLAFAMAB, Clinical Chemistry & Immunoassay Laboratories. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireInnatoss Laboratories lance un service public de dépistage des anticorps neutralisants contre le SRAS-CoV-2 en Europe à l'aide de la trousse cPass™ de GenScriptInnatoss Laboratories announced the launch of Europe's first public SARS-CoV-2 neutralising antibody testing service using GenScript's cPass™ kit, making it the first laboratory in Europe to offer this service to the general public. A study conducted in Kessel, Netherlands found that while binding antibody levels declined significantly over time in 90% of individuals, functional neutralising antibody levels remained stable in 70% of tested cases, suggesting lasting immunity in a majority of recovered patients. The cPass™ kit is the world's first rapid test capable of detecting neutralising antibodies without requiring a biosafety level 3 laboratory.PR NewswireInnatoss Laboratories udostępniają w Europie możliwość robienia badań pod kątem przeciwciał neutralizujących SARS-CoV-2 przy pomocy opracowanego przez GenScript zestawu cPass™Innatoss Laboratories announced the availability of the first in Europe publicly available SARS-CoV-2 neutralizing antibody testing service based on GenScript's cPass™ detection kit, making it the world's first commercially available rapid test for neutralizing antibodies. A study conducted in Kessel, southern Holland, found that binding antibodies declined significantly in 90% of recovered patients over 2–7 months post-infection, while functional neutralizing antibodies remained stable in 70% of participants. The cPass™ kit delivers gold-standard-quality results without requiring BSL-3 laboratory infrastructure, enabling broader global access to reliable COVID-19 immunity monitoring.PR NewswireInnatoss Laboratories startet Test zum Nachweis von neutralisierenden Antikörpern mit dem cPass™ Kit von GenScript gegen SARS-CoV-2 in EuropaInnatoss Laboratories announced the launch of a new neutralizing antibody test service for SARS-CoV-2 in Europe, utilizing GenScript's cPass™ kit. This collaboration marks Innatoss as the first medical laboratory in Europe to offer this specific diagnostic capability to the general public. The test aims to monitor immunity levels and support vaccine development by detecting functional antibodies without requiring Biosafety Level 3 facilities.PR NewswireInnatoss Laboratories lanza un servicio de test de anticuerpos neutralizantes de SARS-CoV-2Innatoss Laboratories announced the launch of Europe's first public service for testing neutralising antibodies against SARS-CoV-2, using GenScript's cPass™ kit. The cPass kit is the world's first commercially available rapid test capable of detecting neutralising antibodies without requiring a Biosafety Level 3 laboratory. A study conducted in Kessel, Netherlands found that while binding antibody levels dropped significantly in 90% of cases over 2-4 months, neutralising antibody levels remained stable in 70% of those tested.PR NewswireInnatoss Laboratories přichází na evropský trh s veřejnou službou na testování protilátek na SARS-CoV-2 se sadou GenScript's cPass™Innatoss Laboratories has launched the first public service for SARS-CoV-2 neutralizing antibody testing in Europe using GenScript's cPass™ kit. This kit is the first commercially available product that enables rapid detection of specific neutralizing antibodies, which help combat viral infections. The service aims to enhance quality testing in response to the COVID-19 pandemic and contribute to vaccine development.PR NewswireInnatoss Laboratories lanza servicio de pruebas públicas de anticuerpos neutralizantes de SARS-CoV-2 en Europa mediante el kit cPass™ de GenScriptInnatoss Laboratories announced the launch of Europe's first public SARS-CoV-2 neutralizing antibody testing service using GenScript's cPass™ kit, which is the world's first rapid test capable of detecting neutralizing antibodies without requiring a biosafety level 3 laboratory. A study conducted in Kessel, Netherlands found that while binding antibody levels decreased significantly in 90% of recovered COVID-19 patients over two to three months, functional neutralizing antibody levels remained stable in 70% of analyzed cases.PR NewswireInnatoss Laboratories внедряет общедоступный сервис тестирования на нейтрализующие антитела к вирусу SARS-CoV-2 в Европе с использованием тест-системы cPass™ фирмы GenScriptInnatoss Laboratories announced the launch of Europe's first public SARS-CoV-2 neutralizing antibody testing service using GenScript's cPass™ test kit, a product that enables rapid detection of neutralizing antibodies (NAbs) without requiring a biosafety level-3 laboratory. The company conducted a study in Kessel, Netherlands, finding that while binding antibody levels declined significantly over time in 90% of recovered COVID-19 patients, functional neutralizing antibody levels remained stable in 70% of subjects, suggesting lasting immunity in a majority of cases.PR NewswireInnatoss Laboratories Launches Neutralizing Antibody Public Testing Service for SARS-CoV-2 in Europe using GenScript's cPass™ kitInnatoss Laboratories announced the launch of Europe's first neutralizing antibody testing service for SARS-CoV-2 for the public, using GenScript's cPass™ kit, which detects the specific antibodies responsible for clearing viral infection. The companies conducted a study in Kessel, Netherlands showing that while binding antibodies declined in 90% of recovered patients, neutralizing antibodies remained stable in 70% of those tested over a 2-3 month period. The cPass™ test produces results equivalent to the gold standard live virus neutralization test without requiring BioSafety level 3 laboratory infrastructure, potentially enabling population-scale immunity monitoring once vaccination is implemented.